<scp>JAK</scp>‐inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report
Sarcoidosis is an inflammatory, non-caseating granulomatous multisystem disease associated with JAK-STAT (Janus kinases-signal transducer and activator of transcription proteins) pathway activation. We present a patient with severe multi-systemic sarcoidosis who showed marked improvement with tofacitinib with regards to pulmonary, cutaneous, nasal and laryngeal disease. Tofacitinib prevented critical laryngeal stenosis from progressing to tracheostomy, induced regression of cutaneous lesions and improved pulmonary function in this steroid-resistant and immunosuppressive intolerant case. This case report supports further the role of JAK-inhibitors in the treatment of systemic sarcoidosis. Laryngoscope, 135:829-832, 2025.
Authors
- Vasileios Kouranos (ORCID: https://orcid.org/0000-0002-2723-0928)
- Hesham Saleh (ORCID: https://orcid.org/0000-0003-2635-2226)
- Nilesh Morar
- Meryem Demir (ORCID: https://orcid.org/0000-0003-2915-6300)
- Stephen R. Durham (ORCID: https://orcid.org/0000-0001-5264-6207)
- Chadwan Al Yaghchi (ORCID: https://orcid.org/0000-0002-5771-5096)
- Guy W. Scadding
- Kostadin Stoenchev
- Guri Sandhu
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- Charing Cross Hospital (GB)
- Ege University (TR)
- Royal Brompton Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- The Laryngoscope
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/lary.31778
- Citations
- 2
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 0.65
Funders
- European Academy of Allergy and Clinical Immunology